GNE-616 , CAS No.G610616, Channel blocker of Na v1.1;Channel blocker of Na v1.2;Channel blocker of Na v1.3;Channel blocker of Na v1.4;Channel blocker of Na v1.5;Channel blocker of Na v1.6;Channel blocker of Na v1.7

Item Number
G610616
Grouped product items
SKUSizeAvailabilityPrice Qty
G610616-5mg
5mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$680.90
G610616-25mg
25mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$2,360.90

Basic Description

Synonymscompound 24;GNE616
Specifications & PurityMoligand™
GradeMoligand™
Action TypeCHANNEL BLOCKER
Mechanism of actionChannel blocker of Na v1.1;Channel blocker of Na v1.2;Channel blocker of Na v1.3;Channel blocker of Na v1.4;Channel blocker of Na v1.5;Channel blocker of Na v1.6;Channel blocker of Na v1.7

Associated Targets(Human)

SCN2A Tclin Sodium channel protein type 2 subunit alpha (1 Activities)
Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)
SCN5A Tclin Sodium channel protein type 5 subunit alpha (0 Activities)
Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)
SCN3A Tclin Sodium channel protein type 3 subunit alpha (0 Activities)
Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)
SCN9A Tclin Sodium channel protein type 9 subunit alpha (2 Activities)
Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)
SCN4A Tclin Sodium channel protein type 4 subunit alpha (0 Activities)
Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)
SCN1A Tclin Sodium channel protein type 1 subunit alpha (0 Activities)
Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)
SCN8A Tclin Sodium channel protein type 8 subunit alpha (1 Activities)
Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)
SCN1A Tclin Sodium channel protein type I alpha subunit (483 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
SCN5A Tclin Sodium channel protein type V alpha subunit (3462 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

Scn2a Sodium channel protein type II alpha subunit (191 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Scn3a Sodium channel protein type III alpha subunit (24 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Scn9a Sodium channel protein type IX alpha subunit (69 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Scn8a Sodium channel protein type VIII alpha subunit (53 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Scn10a Sodium channel protein type X alpha subunit (425 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Scn4a Sodium channel protein type IV alpha subunit (55 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Mus musculus (284745 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Names and Identifiers

IUPAC Name (4S)-6-fluoro-4-[(2R,4S)-2-(pyridin-2-yl)-4-(trifluoromethyl)piperidin-1-yl]-N-(pyrimidin-4-yl)-3,4-dihydro-2H-1-benzopyran-7-sulfonamide
INCHI InChI=1S/C24H23F4N5O3S/c25-17-12-16-19(33-9-5-15(24(26,27)28)11-20(33)18-3-1-2-7-30-18)6-10-36-21(16)13-22(17)37(34,35)32-23-4-8-29-14-31-23/h1-4,7-8,12-15,19-20H,5-6,9-11H2,(H,29,31,32)/t15-,19-,20+/m0/s1
InChi Key XQUOWYVEKSXNET-RYGJVYDSSA-N
Canonical SMILES Fc1cc2c(cc1S(=O)(=O)Nc1ccncn1)OCC[C@@H]2N1CC[C@@H](C[C@@H]1c1ccccn1)C(F)(F)F
Isomeric SMILES C1CN([C@H](C[C@H]1C(F)(F)F)C2=CC=CC=N2)[C@H]3CCOC4=CC(=C(C=C34)F)S(=O)(=O)NC5=NC=NC=C5
PubChem CID 138393286

Certificates

Certificate of Analysis(COA)

Enter Lot Number to search for COA:

Related Documents

References

1. Goldberg YP, MacFarlane J, MacDonald ML, Thompson J, Dube MP, Mattice M, Fraser R, Young C, Hossain S, Pape T, Payne B, Radomski C, Donaldson G, Ives E, Cox J, Younghusband HB, Green R, Duff A, Boltshauser E, Grinspan GA, Dimon JH, Sibley BG, Andria G, Toscano E, Kerdraon J, Bowsher D, Pimstone SN, Samuels ME, Sherrington R, Hayden MR.  (2007)  Loss-of-function mutations in the Nav1.7 gene underlie congenital indifference to pain in multiple human populations..  Clin Genet,  71  (4): (311-9).  [PMID:17470132] [10.1021/op500134e]
2. Cox JJ, Reimann F, Nicholas AK, Thornton G, Roberts E, Springell K, Karbani G, Jafri H, Mannan J, Raashid Y et al..  (2006)  An SCN9A channelopathy causes congenital inability to experience pain..  Nature,  444  (7121): (894-8).  [PMID:17167479] [10.1021/op500134e]
3. Bagal SK, Chapman ML, Marron BE, Prime R, Storer RI, Swain NA.  (2014)  Recent progress in sodium channel modulators for pain..  Bioorg Med Chem Lett,  24  (16): (3690-9).  [PMID:25060923] [10.1021/op500134e]
4. Gingras J, Smith S, Matson DJ, Johnson D, Nye K, Couture L, Feric E, Yin R, Moyer BD, Peterson ML et al..  (2014)  Global Nav1.7 knockout mice recapitulate the phenotype of human congenital indifference to pain..  PLoS ONE,  (9): (e105895).  [PMID:25188265] [10.1021/op500134e]
5. McKerrall SJ, Sutherlin DP.  (2018)  Nav1.7 inhibitors for the treatment of chronic pain..  Bioorg Med Chem Lett,  28  (19): (3141-3149).  [PMID:30139550] [10.1021/op500134e]
6. Shields SD, Deng L, Reese RM, Dourado M, Tao J, Foreman O, Chang JH, Hackos DH.  (2018)  Insensitivity to Pain upon Adult-Onset Deletion of Nav1.7 or Its Blockade with Selective Inhibitors..  J Neurosci,  38  (47): (10180-10201).  [PMID:30301756] [10.1021/op500134e]
7. McKerrall SJ, Nguyen T, Lai KW, Bergeron P, Deng L, DiPasquale A, Chang JH, Chen J, Chernov-Rogan T, Hackos DH et al..  (2019)  Structure- and Ligand-Based Discovery of Chromane Arylsulfonamide Nav1.7 Inhibitors for the Treatment of Chronic Pain..  J Med Chem,  62  (8): (4091-4109).  [PMID:30943032] [10.1021/op500134e]

Solution Calculators